Indivior PLC
LSE:INDV
Indivior PLC
Operating Income
Indivior PLC
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Indivior PLC
LSE:INDV
|
Operating Income
$287m
|
CAGR 3-Years
12%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-7%
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Operating Income
£8.1B
|
CAGR 3-Years
12%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
4%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Operating Income
$12.7B
|
CAGR 3-Years
37%
|
CAGR 5-Years
27%
|
CAGR 10-Years
19%
|
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Operating Income
-$154.6m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Operating Income
$629m
|
CAGR 3-Years
4%
|
CAGR 5-Years
6%
|
CAGR 10-Years
5%
|
|
|
A
|
Alliance Pharma PLC
LSE:APH
|
Operating Income
£33.4m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
11%
|
|
Indivior PLC
Glance View
Indivior PLC, a pivotal player in the pharmaceutical landscape, traces its roots back to a dedicated focus on addiction treatment. With an origin steeped in addressing opioid dependency, the company carved out a significant niche by developing and marketing medication-assisted treatments. At the heart of Indivior's success is its flagship product, Suboxone, which combines buprenorphine and naloxone to manage opioid addiction. This formulation, integral in combating withdrawal symptoms and reducing the allure of opioids, positioned Indivior as an innovator in an era when the opioid crisis commanded urgent attention. The company's revenue model leverages the growing need for comprehensive drug dependence solutions, primarily driven by its robust portfolio of treatment options. By relentlessly advocating for effective healthcare policies and ensuring substantial product availability, Indivior maintains its competitive edge. The company's strategy is not just confined to novel drug development, but also focuses on expanding treatment access globally, aligning profitability with public health imperatives. This dual commitment to innovation and societal impact ensures that Indivior remains a significant force in the healthcare sector, adeptly navigating the complexities of addiction treatment while generating sustainable financial growth.
See Also
What is Indivior PLC's Operating Income?
Operating Income
287m
USD
Based on the financial report for Dec 31, 2024, Indivior PLC's Operating Income amounts to 287m USD.
What is Indivior PLC's Operating Income growth rate?
Operating Income CAGR 10Y
-7%
Over the last year, the Operating Income growth was 4%. The average annual Operating Income growth rates for Indivior PLC have been 12% over the past three years , 7% over the past five years , and -7% over the past ten years .
You don't have any saved screeners yet